Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5960
    +0.0023 (+0.39%)
     
  • NZD/EUR

    0.5554
    +0.0008 (+0.15%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.84
    +0.03 (+0.04%)
     
  • GOLD

    2,338.50
    +0.10 (+0.00%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,088.92
    +48.54 (+0.60%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    17,968.50
    -120.20 (-0.66%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • NZD/JPY

    92.6970
    +0.5820 (+0.63%)
     

Novartis to Divest Portions of Sandoz US to Aurobindo

Novartis to Divest Portions of Sandoz US to Aurobindo

Novartis (NVS) announced today, September 6, that it has agreed to sell select portions of its Sandoz US portfolio to Aurobindo Pharma USA for $0.9 billion in cash and $0.1 billion in potential earn-outs. The select portions include the Sandoz US dermatology business and the generic US oral solids business. The deal includes ~300 products and additional development programs that will be transferred from Sandoz’s US portfolio to Aurobindo.